
This Longevity Molecule Extends Primate Lifespan by 15% | Dr. Adam Salmon
In this interview, Dr. Adam Salmon discusses his groundbreaking research on rapamycin in common marmosets, emphasizing their role as a crucial bridge between rodent and human studies.
1. Why Marmosets?
- They develop age-related diseases similar to humans (e.g., cardiovascular disease, kidney disease), unlike mice.
- With a lifespan of 7-9 years, they are short-lived for non-human primates (macaques live 40+ years), making long-term studies feasible.
- They possess genetic diversity approximating human populations.
2. Study Design & Results (yet unpublished)
- Setup: ~70 middle-aged marmosets (human equivalent of ~50-60 years) received a daily high dose of rapamycin or a placebo.
- Lifespan Extension: The rapamycin-treated group lived 10-15% longer – on par with initial successful mouse studies. For humans, this would translate to an average lifespan increase of ~10 years.
- Healthspan: No dramatic improvements were seen across all metrics, but there was a delay in age-related functional decline (e.g., kidney function).
- Positive Side Effects: Treatment delayed cavities and periodontal disease, a result now clinically relevant.
3. Side Effects & Metabolic Impact
- Blood Sugar: Surprisingly, marmosets did not show a sustained increase in blood glucose, contrasting with mice and humans. Dr. Salmon posits the mouse liver plays an outsized role in glucose metabolism.
- Sex-Specific Effects: Female marmosets on rapamycin showed an increased risk of knee osteoarthritis – a novel finding.
- Reversibility: Almost all side effects (e.g., mouth ulcers, high blood sugar) rapidly disappear upon stopping the drug.
4. Outlook & Clinical Relevance
- Intermittent Dosing: Dr. Salmon does not recommend daily rapamycin (due to MTORC2 effects) but advocates for intermittent dosing (e.g., 1-2x/week), as used in current human trials.
- Next Steps: Full data (including cause of death for all animals) will be published by 2027. Tissue samples offer unique insights into molecular effects of lifelong treatment.
- Conclusion: The marmoset study provides proof-of-principle that inhibiting the mTOR pathway has the potential to extend human healthspan with manageable, reversible side effects.






